Crinetics Pharmaceuticals Completes $40M Series A Financing

Crinetics PharmaceuticalsCrinetics Pharmaceuticals, a San Diego, California-based therapeutics company focused on specialty endocrine disorders, completed a $40m Series A financing.

The round was led by 5AM Ventures, Versant Ventures, and Vivo Capital. In conjunction with the funding, Wendell Wierenga, Ph.D. joined Crinetics’ board of directors as chairman along with Mason Freeman, M.D. representing 5AM Ventures, Steve Kaldor, Ph.D. representing Versant Ventures, and Mahendra Shah, Ph.D. representing Vivo Capital, who joined the board.

The company intends to use the funds to advance development of its small molecule somatostatin agonist program to clinical proof-of-concept for the treatment of acromegaly, as well as to move additional programs into development.

Led by Scott Struthers, Ph.D., founder and chief executive officer, Crinetics Pharmaceuticals discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of specialty endocrine disorders in neuroendocrinology, reproductive medicine, and women’s health. Its small molecule somatostatin agonist program for the treatment of acromegaly and neuroendocrine tumors aims to provide an effective oral therapy for patients whose only current options are painful injected depot drugs.

FinSMEs

02/11/2015

Join the discussion